Quinoline-thiosemicarbazone-1,2,3-triazole-acetamide derivatives as new potent α-glucosidase inhibitors
In this work, a novel series of quinoline-thiosemicarbazone-1,2,3-triazole-aceamide derivatives 10a-n as new potent α-glucosidase inhibitors was designed, synthesized, and evaluated. All the synthesized derivatives 10a-n were more potent than acarbose (positive control). Representatively, (E)-2-(4-(((3-((2-Carbamothioylhydrazineylidene)methyl)quinolin-2-yl)thio)methyl)-1H-1,2,3-triazol-1-yl)-N-phenethylacetamide (10n), as the most potent entry, with IC<sub>50</sub> = 48.4 µM was 15.5-times more potent than acarbose. According to kinetic study, compound 10n was a competitive inhibitor against α-glucosidase. This compound formed the desired interactions with important residues of the binding pocket of α-glucosidase with favorable binding energy in the molecular docking and molecular dynamics. Compounds 10n, 10e, and 10 g as the most potent compounds among the synthesized compounds were evaluated in term of pharmacokinetics and toxicity via online servers. These evaluations predicted that compounds 10n, 10e, and 10 g had good pharmacokinetic properties and toxicity profile.
Authors
- Somayeh Mojtabavi (ORCID: https://orcid.org/0000-0003-0584-5478)
- Mohammad Halimi (ORCID: https://orcid.org/0000-0002-7422-2533)
- Mohammad Ali Faramarzi (ORCID: https://orcid.org/0000-0002-8822-453X)
- Navid Dastyafteh
- Maryam Mohammadi‐Khanaposhtani (ORCID: https://orcid.org/0000-0001-7664-9664)
- Milad Noori
- Mohammad Mahdavi (ORCID: https://orcid.org/0000-0002-8007-2543)
- Aynaz Khademian
- Reza Azarbad
- Amir Hossein Alaedini
Institutions
- University of Tehran (IR)
- Islamic Azad University, Babol
- Tehran University of Medical Sciences (IR)
- Babol University of Medical Sciences (IR)
Publication Details
- Journal
- Scientific Reports
- Published
- 2024-12-28
- DOI
- https://doi.org/10.1038/s41598-024-81668-5
- Citations
- 4
- Primary Topic
- Synthesis and biological activity
- Type
- article
- Field-Weighted Citation Impact
- 1.00
Funders
- Babol University of Medical Sciences